Trial Profile
A Multicenter, Fixed-Dose, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of AR19 (Amphetamine Sulfate) in Adult Subjects (Ages 18-55) With Attention Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Amfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Arbor Pharmaceuticals
- 24 Aug 2021 Results published in the Journal of Clinical Psychiatry
- 10 Sep 2020 According to an Arbor Pharmaceuticals media release, data from this study support Arbors New Drug Application (NDA) for AR19.
- 10 Sep 2020 According to an Arbor Pharmaceuticals media release, researchers are presenting this study findings at the 33rd annual Psych Congress, along with new data on the prevalence of and motivations for non-oral misuse and abuse of prescription stimulants among college students.